Human tissue in systems medicine

Histopathology, the examination of an architecturally artefactual, two‐dimensional and static image remains a potent tool allowing diagnosis and empirical expectation of prognosis. Considerable optimism exists that the advent of molecular genetic testing and other biomarker strategies will improve or even replace this ancient technology. A number of biomarkers already add considerable value for prediction of whether a treatment will work. In this short review we argue that a systems medicine approach to pathology will not seek to replace traditional pathology, but rather augment it. Systems approaches need to incorporate quantitative morphological, protein, mRNA and DNA data. A significant challenge for clinical implementation of systems pathology is how to optimize information available from tissue, which is frequently sub‐optimal in quality and amount, and yet generate useful predictive models that work. The transition of histopathology to systems pathophysiology and the use of multiscale data sets usher in a new era in diagnosis, prognosis and prediction based on the analysis of human tissue.

[1]  Leslie H. Sobin,et al.  TNM Classification of Malignant Tumours, 7th Edition , 2009 .

[2]  O. Laerum,et al.  Clinical application of flow cytometry: a review. , 1981, Cytometry.

[3]  Neil O Carragher,et al.  High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells , 2010, Molecular Cancer Therapeutics.

[4]  G. Fontanini,et al.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.

[5]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[6]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. McGuire,et al.  Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. , 1992, Anticancer research.

[8]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[10]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[11]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[12]  L. Hood,et al.  A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. , 2012, New biotechnology.

[13]  V. Speirs,et al.  Breast cancer: Investment biobanking—increased returns from tissue samples , 2013, Nature Reviews Clinical Oncology.

[14]  Andrew Evans,et al.  Digital imaging in pathology: whole-slide imaging and beyond. , 2013, Annual review of pathology.

[15]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.

[16]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[17]  David J. Harrison,et al.  Systems pathology—taking molecular pathology into a new dimension , 2009, Nature Reviews Clinical Oncology.

[18]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[19]  H. Ling KRAS Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer , 2009 .

[20]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Freedman,et al.  A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[22]  F. Markowetz,et al.  Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling , 2012, Science Translational Medicine.

[23]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[24]  J. Brierley Classification of Malignant Tumours , 1963, British medical journal.

[25]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[26]  Igor Goryanin,et al.  Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.

[27]  C. von Wagner,et al.  Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests , 2010, Gut.

[28]  D Faratian,et al.  Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[30]  M. Dowsett,et al.  Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer , 2010, Breast Cancer Research.

[31]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  D. Calvisi,et al.  Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. , 2012, Biochimica et biophysica acta.

[33]  Leslie H. Sobin,et al.  Comprar TNM Classification of Malignant Tumours, 7th Edition | C. Wittekind | 9781444332414 | Wiley , 2009 .

[34]  Marilyn M. Bui,et al.  Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? , 2010, Journal of pathology informatics.

[35]  Girish Venkataraman,et al.  Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method. , 2007, Urology.